Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4104516 | 0.85 | KCNH2 (0.36) | KCNH2KDM4EKMT2AALDH1A1LMNA | |
| SCHEMBL4959656 | 0.82 | PTGDR2 (0.42) | PGRKCNH2KDM4EALDH1A1LMNA | |
| SCHEMBL4609839 | 0.82 | PGR (0.61) | PGRKCNH2KDM4ESCN9A | |
| SCHEMBL4112540 | 0.82 | PGR (0.38) | PGRKCNH2KDM4EKMT2AMAPT | |
| SCHEMBL4608810 | 0.81 | PGR (0.34) | PGRSLC22A12KDM4EKMT2AMAPT | |
| SCHEMBL4099713 | 0.81 | PGR (0.42) | PGRKCNH2KDM4EKMT2AALDH1A1 | |
| SCHEMBL4102616 | 0.81 | PGR (0.39) | PGRKCNH2KDM4EKMT2AMAPT | |
| SCHEMBL9997811 | 0.81 | PGR (0.35) | PGRKDM4EKMT2AMEN1 | |
| SCHEMBL4607901 | 0.80 | KCNH2 (0.33) | KCNH2MAPK1SMN1; SMN2 | |
| SCHEMBL4102883 | 0.80 | PGR (0.44) | PGRKCNH2SLC22A12KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | claimed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | claimed |
| EP-1948615-A2 | COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2008-07-30 | — | — | EP | claimed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | claimed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| WO-2007054770-A2 | PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE | PFIZER LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | claimed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105909-A1 | Compounds useful in therapy | GNRHR, OPRK1, CBR3 | PGR 155/4885KCNH2 378/4885SLC22A12 4235/4885 |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | CBR3, GNRHR, RXFP3 | PGR 87/4885KCNH2 262/4885SLC22A12 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.